secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001193125-25-122456
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO closes up to $250M royalty bond with HCRx; $150M funded, cash runway into early 2027
--------------------------------------------------------------------------------

- Received $150M at closing; up to $250M total via three tranches, including $50M contingent on Zolgensma sales threshold by Apr 2027.
- Royalty bond bears interest at 9.75% + 3-month SOFR (4.25% floor); repayment solely from royalties on Zolgensma, RGX-121, RGX-111, and NAV platform licensees.
- Issued HCRx warrant for 268,096 shares at $14.92 (100% premium to 30-day VWAP), exercisable for 10 years.
- Extends expected cash runway into early 2027, funding late-stage programs including RGX-121, RGX-202, and ABBV-RGX-314.
- Retains future non-dilutive sources: potential Priority Review Voucher for RGX-121 and milestones from AbbVie and Nippon Shinyaku.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312525122456/0001193125-25-122456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312525122456/d31892d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-122456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer